Medications for Gastrointestinal Stromal Tumors

9 results

  • ayvakit

    (avapritinib)
    Blueprint Medicines Corporation
    AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.

  • imatinib mesylate

    (IMATINIB MESYLATE)
    Camber Pharmaceuticals, Inc.
    This drug is indicated for treating newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).

  • imatinib mesylate

    (Imatinib Mesylate)
    BluePoint Laboratories
    This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.

  • imatinib mesylate

    (imatinib mesylate)
    Archis Pharma LLC
    This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.

  • imatinib mesylate

    (imatinib mesylate)
    Qilu Pharmaceutical Co., Ltd.
    This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.

  • imatinib mesylate

    (Imatinib Mesylate)
    American Health Packaging
    This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML in various phases post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) in adults, and newly diagnosed Ph+ ALL in pediatric patients, among other specific malignancies.

  • imatinib mesylate

    (imatinib)
    Mylan Pharmaceuticals Inc.
    This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).

  • qinlock

    (Ripretinib)
    Deciphera Pharmaceuticals, LLC
    QINLOCK is indicated for adult patients with advanced gastrointestinal stromal tumor (GIST) who have previously been treated with three or more kinase inhibitors, including imatinib.

  • sutent

    (Sunitinib malate)
    Pfizer Laboratories Div Pfizer Inc
    SUTENT is indicated for adult patients with gastrointestinal stromal tumors (GIST) after imatinib failure, advanced renal cell carcinoma (RCC), adjuvant treatment in high-risk recurrent RCC post-nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumors (pNET) in unresectable locally advanced or metastatic cases.